Roger Tell
Chief Tech/Sci/R&D Officer presso ISOFOL MEDICAL AB
Posizioni attive di Roger Tell
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| ISOFOL MEDICAL AB | Chief Tech/Sci/R&D Officer | 01/02/2019 | - |
| Chief Executive Officer | 22/06/2023 | 09/01/2024 | |
| VIVESTO AB | Director/Board Member | 25/05/2022 | - |
Storia della carriera di Roger Tell
Precedenti posizioni note di Roger Tell
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
Aprea Therapeutics AB
 Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden. | Corporate Officer/Principal | - | 01/02/2019 |
Formazione di Roger Tell
| Karolinska Institutet | Doctorate Degree |
Statistiche
Distribuzione geografica
| Svezia | 5 |
Posizioni
| Chief Executive Officer | 1 |
| Chief Tech/Sci/R&D Officer | 1 |
| Corporate Officer/Principal | 1 |
Settori
| Health Technology | 4 |
| Consumer Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| VIVESTO AB | Health Technology |
| ISOFOL MEDICAL AB | Health Technology |
| Aziende private | 1 |
|---|---|
Aprea Therapeutics AB
Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden. | Health Technology |
- Borsa valori
- Insiders
- Roger Tell
- Esperienza
